HOTAIR and myeloid sarcoma: Further, increased expression of HOTAIR has been observed in PBMCs of relapse-remitting MS subjects in the relapse phase, indicating that it could serve as a potential biomarker to differentiate the remit and relapse phases of these subjects (Soltanmoradi et al. 2021).